Neoadjuvant Carboplatin, Paclitaxel (Taxol) and Pembrolizumab Treatment Regimen
Reading tools
In this article
What Is Neoadjuvant Carboplatin + Paclitaxel (Taxol) + Pembrolizumab Treatment?
This treatment is a potent combination given before surgery to shrink the tumor and improve disease control. Combining three different drugs both directly targets cancer cells and strengthens the immune system's fight against cancer.
The goal of neoadjuvant treatment
Before surgery, the goals are to:
- Shrink the tumor as much as possible,
- Increase the likelihood of complete tumor removal during surgery,
- Reduce the long-term risk of the disease returning (recurrence).
What Do These Drugs Do?
1️⃣ Paclitaxel (Taxol): A Drug That Stops Cancer Cell Division
Paclitaxel targets cancer cell division and proliferation . By binding to structural components inside the cell, it prevents normal cell division. A cancer cell unable to divide eventually loses viability and dies.
Paclitaxel in brief:
- Slows cancer cell growth and proliferation,
- Locks the cell in the “division phase,” leading to its death.
2️⃣ Carboplatin: A Drug That Damages Cancer Cell DNA
Carboplatin works by damaging the DNA of cancer cells. Cells with damaged DNA cannot repair themselves and die over time.
Carboplatin in brief:
- Damages the cancer cell's genetic material (DNA),
- Disrupts the cell's ability to repair itself and proliferate,
- Ultimately leads to programmed cell death.
3️⃣ Pembrolizumab: Immunotherapy That Strengthens the Immune System
Pembrolizumab is an immunotherapy drug. Its role is to reactivate the immune system to fight cancer.
Cancer cells use certain proteins to “hide” from the immune system. Pembrolizumab binds to the PD-1 receptor on T cells, disrupting this concealment mechanism. As a result:
- Immune cells begin to recognize cancer cells again,
- The body mounts a stronger attack against cancer cells.
How Does the Triple Combination Work Together?
Immunotherapy–chemotherapy synergy
The strength of this triple treatment comes from the drugs' complementary effects :
- Carboplatin and paclitaxeldirectly kill cancer cells, while fragments of these cells are also “presented” to the immune system.
- Pembrolizumabreactivates immune cells at the same time, counteracts their exhaustion and helps generate a stronger, longer-lasting response against cancer cells.
The goals of this combination are therefore to:
- Shrink the tumor as much as possible before surgery,
- Increase the pathological complete response rate (no viable cells remaining in the tumor),
- Extend long-term disease-free and overall survival,
- Reduce the risk of recurrence.
Treatment goals
- Increase the pathological complete response (pCR) rate and thereby achieve long-term EFS/DFS/OS benefits.
- Reduce tumor volume to improve surgical resectability and, where possible, allow breast-conserving surgery or more limited resections.
- In locally advanced disease, use downstaging to reduce nodal burden.
- Use the neoadjuvant response to individualize post-neoadjuvant (adjuvant) strategies (for example, additional treatments for residual disease).
- In NSCLC and other selected solid tumors, use perioperative immunotherapy–chemotherapy to target early micrometastatic disease.
Indications and Place in Guidelines
- 1) High-risk early-stage triple-negative breast cancer (TNBC)
- In high-risk early-stage TNBC with a T stage ≥T1c and/or positive nodes (N+), carboplatin + paclitaxel + pembrolizumab has become one of the standard regimens in the first phase of neoadjuvant treatment.
- The KEYNOTE-522 study and follow-up analyses have shown that this regimen significantly increases the pCR rate and provides a long-term event-free survival (EFS) advantage .
- Many guidelines (NCCN, ESMO, etc.) recommend neoadjuvant pembrolizumab + carboplatin/paclitaxel followed by anthracycline + cyclophosphamide (AC) + adjuvant pembrolizumab in eligible patients.
- 2) Resectable early-stage/locally advanced non-small cell lung cancer (NSCLC; perioperative approach)
- According to FDA approval and international guidelines, resectable (T ≥4 cm or N+) NSCLC can be treated with platinum-containing chemotherapy + pembrolizumab in the neoadjuvant setting, followed by adjuvant pembrolizumab after surgery, as a new standard treatment option .
- Although the chemotherapy regimens used in most studies are cisplatin-based , in clinical practice, for cisplatin-intolerant patients, regimens such as carboplatin + paclitaxel may be used on an individualized basis according to patient characteristics.
- 3) Metastatic squamous NSCLC (1st line; not neoadjuvant)
- In metastatic squamous NSCLC, carboplatin + (paclitaxel or nab-paclitaxel) + pembrolizumabis, based on the KEYNOTE-407 study, among the category 1, “preferred” 1st-line options.
- This use is not neoadjuvant, but systemic treatment for metastatic disease; the same drug combination plays a role in a different clinical setting.
- Other solid tumors: In selected studies and phase II protocols, carboplatin/paclitaxel + pembrolizumab is being investigated, particularly in emerging indications . However, in these settings, standard treatment should not be departed from, and current guidelines and national approval/reimbursement status must be checked.
Note: This summary is based on current major phase III trials and international guidelines; indications may vary by country and over time.
SGK Reimbursement Status
- Pembrolizumab: In Turkey, various cancer types (particularly lung cancer, melanoma and certain GI and GU tumors, etc.) have specific indications reimbursed by SGK. With PD-L1(+) CPS ≥ 10 on a validated test,metastatic or unresectable locally recurrent triple-negative breast cancer is reimbursed with a medical report when used in combination with chemotherapy as first-line treatment. For reimbursement conditions, see: https://www.drozdogan.com/keytruda-pembrolizumab-immunoterapisi-nedir-ne-icin-kullanilir/.
- Carboplatin and Paclitaxel: These chemotherapy drugs have long been used for many solid tumor indications and are generally covered by SGK . However, conditions such as the specific indication, treatment line, ECOG performance status and wording of the medical report are important for reimbursement.
- In clinical practice, particularly for regimens containing costly immunotherapy, preparing a multidisciplinary tumor board decision and a detailed oncology report for each case facilitates the reimbursement process.
Dose and Administration Sequence
A KEYNOTE-522-like neoadjuvant plan generally involves 4 cycles of carboplatin + paclitaxel + pembrolizumab (each cycle lasts 21 days), followed by anthracycline + cyclophosphamide (AC) + pembrolizumab .
- Pembrolizumab: 200 mg IV, Every 3 weeks (day 1), given before chemotherapy or on the same day.
- Paclitaxel (Taxol): 80 mg/m² IV, Once weekly (days 1, 8, 15). Infusion usually lasts 60 minutes (premedication is essential). Alternatively, depending on the institution and patient circumstances, 175 mg /m2 every 3 weeks may be given.
- Carboplatin:
- 3-weekly dose: AUC 5–6 IV, on day 1 (the most common approach).
- Alternative: Weekly AUC 1.5–2, on days 1, 8, 15 (may be used in some protocols).
- Duration: 4 cycles (approximately 12 weeks) of carboplatin/paclitaxel + pembrolizumab → followed by 4 cycles of AC + pembrolizumab → surgery → depending on residual disease, adjuvant pembrolizumab to complete a total of 1 year of treatment.
Premedication & Supportive Care:
- Before Paclitaxel: Dexamethasone, H1 and H2 blockers (e.g., diphenhydramine, ranitidine, etc.) for hypersensitivity prophylaxis.
- Antiemetics: Because the regimen carries a moderate–high emetogenic risk, a 5-HT3 antagonist + dexamethasone ± NK1 antagonist combination is considered (depending on carboplatin dose and institutional protocol).
- Support: G-CSF prophylaxis is considered, particularly for patients at high risk of febrile neutropenia, older/frail patients or those with comorbidities.
Pretreatment Assessments and Monitoring
- Laboratory tests: Complete blood count, creatinine/eGFR, AST/ALT/ALP/bilirubin, electrolytes, fasting glucose, thyroid function tests (TSH, fT4) and cortisol when indicated. Before chemotherapy, kidney function is critical for carboplatin dosing.
- Performance status and comorbidities: ECOG performance status, cardiovascular disease, diabetes, history of autoimmune disease and chronic infections (HBV/HCV/HIV, etc.) must be assessed.
- Imaging: Baseline breast and axillary imaging (MRI, ultrasound, mammography) and systemic staging (CT, PET-CT when indicated). In NSCLC, chest CT/PET-CT + brain imaging are important.
- Response assessment: During neoadjuvant treatment, response is generally assessed every 8–12 weeks clinically and through imaging; restaging is performed before surgery.
- During follow-up: Complete blood count + biochemistry before each cycle; at every visit assess blood pressure, weight, performance status and signs of immune-related toxicity (diarrhea, rash, dyspnea, endocrine symptoms, etc.).
Precautions During Administration
- Paclitaxel hypersensitivity reactions: Dyspnea, flushing, chest tightness or hypotension may develop within the first minutes of infusion. Stop the infusion immediatelyand administer IV antihistamines, steroids and adrenaline if necessary; decide whether to change the regimen/rechallenge in subsequent cycles according to severity.
- Peripheral neuropathy: Closely monitor paclitaxel-related numbness/burning in the hands and feet; for G2–3 symptoms, consider extending dosing intervals or reducing the dose, and changing the drug if necessary.
- Hematologic toxicity: Frequent blood counts to monitor neutropenia and thrombocytopenia; at G3–4, plan cycle delays, dose reductions and G-CSF treatment.
- Pembrolizumab-related immune adverse effects: Immune-related colitis, hepatitis, pneumonitis and endocrinopathies (hypo/hyperthyroidism, hypophysitis, adrenal insufficiency) require education of patients and the care team. Consider irAEs with prolonged diarrhea, new dyspnea/cough, unexplained transaminase elevation, persistent fatigue and headache.
- Surgical planning: After completion of the neoadjuvant phase, close communication among medical oncology, surgery and radiology teams is necessary to optimize surgical timing. Immunotherapy is generally stopped before surgery with a specified interval after the final dose ; institutional protocols and surgeon/oncologist preferences matter.
Drug Interactions
- Paclitaxel: Metabolized through CYP2C8 and CYP3A4. Strong CYP3A4 inhibitors (azole antifungals, macrolides, etc.) may increase blood levels; inducers (rifampicin, carbamazepine, etc.) may reduce efficacy. With anticoagulants, the risk of bleeding may increase, requiring close monitoring.
- Carboplatin: Does not undergo substantial CYP-mediated metabolism; concomitant nephrotoxic drugs (aminoglycosides, some NSAIDs, etc.) increase the risk of renal toxicity. Combining it with other myelosuppressive agents intensifies bone marrow suppression .
- Pembrolizumab: Classical cytochrome P450 interactions are minimal; however, systemic high-dose corticosteroids (without an indication other than immune toxicity) may weaken the immune response. Vaccination and infection management should be individualized.
Special Clinical Considerations
- Renal impairment: Carboplatin dosing should be adjusted according to GFR-based AUC calculations. In severe renal impairment (e.g., GFR <30 mL/min), the regimen should be reassessed.
- Cardiac comorbidities: Considering paclitaxel together with the anthracycline phase, cardiac function (ECG, echocardiography) should be assessed before and during treatment.
- Active autoimmune diseases: Pembrolizumab requires careful consideration in patients with moderate–severe active autoimmune disease or chronic high-dose immunosuppression.
- Pregnancy and fertility: Both chemotherapy and immunotherapy are fetotoxic; during treatment and for an appropriate period afterward, effective contraception is recommended. Fertility preservation (oocyte/embryo cryopreservation, etc.) must be discussed before treatment.
- Older and frail patients: Dose intensity and the extent of combination treatment should be adapted according to comorbidities and functional status.
Approach to Dose Modification
| Condition | Recommended Approach | Note |
|---|---|---|
| G3–4 neutropenia or febrile neutropenia | Delay the cycle; consider a reduction in paclitaxel and carboplatin doses of − 20% ; initiate G-CSF prophylaxis. | Resume treatment when ANC ≥1500/mm³; reduce further for recurrent events. |
| G3–4 thrombocytopenia | Reduce carboplatin dosing by − 20–25% or omit a cycle. | Delay treatment if bleeding occurs; give platelet concentrate if necessary. |
| G2 peripheral neuropathy (Paclitaxel) | Reduce the paclitaxel dose by − 20% or extend the dosing interval. | For G3 neuropathy, consider stopping/changing paclitaxel. |
| G3–4 immune-related colitis / hepatitis / pneumonitis (Pembrolizumab) | Pembrolizumab: stop immediately; high-dose IV steroids (e.g., methylprednisolone 1–2 mg/kg/day) + gradual taper. | Pembrolizumab may be permanently discontinued in severe or recurrent cases; consultation with the relevant specialist (gastroenterology, pulmonology, hepatology) is recommended. |
| G2 immune-related toxicities (prolonged) | Temporarily withhold; closely monitor with low–moderate-dose steroids. | Careful resumption after improvement; reassess if symptoms recur. |
| Severe hypersensitivity (anaphylaxis) Paclitaxel or Carboplatin | Permanently stop administration for that cycle; consider an alternative regimen or desensitization protocol. | Manage in a setting equipped for resuscitation; determine subsequent treatment through multidisciplinary decision-making. |
Adverse Effect Frequency and Practical Management Tips
>20% Very common 10–20% Common 1–10% Less common <1% Rare/serious
Paclitaxel (Taxol)
| Frequency | Adverse Effect | Practical Tip |
|---|---|---|
| >20% | Peripheral neuropathy | Regular neurological assessments; dose reduction or drug substitution at G2–3; B6/B12 and supportive treatments. |
| >20% | Alopecia, fatigue | Provide information beforehand; support with wigs/head coverings; energy management and exercise advice. |
| 10–20% | Hypersensitivity reactions | Adhere to premedication; closely monitor initial infusions; intervene promptly if a reaction occurs. |
| 10–20% | Myelosuppression (neutropenia, anemia) | Regular blood counts; infection prophylaxis; G-CSF and red blood cell transfusion if necessary. |
| 1–10% | Onycholysis, muscle-joint pain | Symptomatic analgesia; nail care; protective measures such as cold gloves/socks may be considered. |
Carboplatin
| Frequency | Adverse Effect | Practical Tip |
|---|---|---|
| >20% | Thrombocytopenia, neutropenia | Regular blood counts, dose adjustment, G-CSF and platelet concentrate if necessary. |
| 10–20% | Myalgia, nausea-vomiting | Effective antiemetic prophylaxis; simple analgesics; hydration. |
| 1–10% | Hypomagnesemia, hyponatremia | Monitor electrolytes; oral/IV replacement if necessary. |
| <1% | Allergic reactions (delayed) | Careful monitoring with prolonged exposure and cumulative doses; change the regimen or use desensitization if a reaction develops. |
Pembrolizumab
| Frequency | Adverse Effect | Practical Tip |
|---|---|---|
| >20% | Fatigue, mild rash, pruritus | Mild topical steroids/antihistamines; lifestyle adjustments; close monitoring. |
| 10–20% | Hypothyroidism/hyperthyroidism | Regular TSH and fT4 monitoring; thyroid replacement or antithyroid treatment if symptomatic. |
| 1–10% | Immune-related colitis, hepatitis | Stool tests and imaging for persistent diarrhea or transaminase elevation; initiate steroids early. |
| 1–10% | Immune-related pneumonitis | Chest CT for new/worsening dyspnea, cough or hypoxia; pulmonology consultation and steroid treatment. |
| <1% | Severe endocrinopathies (hypophysitis, adrenal insufficiency), neurological irAEs | Urgent multidisciplinary management; high-dose steroids and other immunosuppressants if necessary; permanent pembrolizumab discontinuation may be considered. |
Frequencies may vary by clinical trial and combination; approximate categories are summarized here.
The neoadjuvant carboplatin + paclitaxel + pembrolizumab regimen is a potent option for various solid tumors, particularly high-risk early-stage TNBC , with appropriate patient selection, multidisciplinary planning and proactive toxicity management. The degree of pathological response plays a critical role in determining long-term recurrence risk and adjuvant strategies. Treatment planning must always consider current guidelines, approval and reimbursement conditions .
References
1) Schmid P, et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med. 2020.
2) KEYNOTE-522 Investigators. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in early TNBC – long-term results and updates.
3) NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, v.2025 – TNBC neoadjuvant immunotherapy recommendations.
4) FDA and EMA product information: Pembrolizumab (KEYTRUDA) – TNBC and NSCLC perioperative/metastatic indications.
5) Paz-Ares L, et al. Pembrolizumab plus chemotherapy for metastatic squamous NSCLC (KEYNOTE-407). N Engl J Med. 2018 and final analysis updates.
6) Wakelee H, et al. Perioperative pembrolizumab for resectable NSCLC (KEYNOTE-671). N Engl J Med. 2023 and follow-up analyses.
7) Current national and international chemotherapy protocol documents (eviQ, NCCP, etc.) – Carboplatin + Paclitaxel + Pembrolizumab dosing schedules.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.